

# Italy

Population 2018

61 million

Estimates of TB burden <sup>o</sup> , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	4.3 (3.7–4.9)	7 (6–8.1)
HIV-positive TB incidence	0.2 (0.11–0.32)	0.34 (0.19–0.53)
MDR/RR-TB incidence <sup>oo</sup>	0.17 (0.11–0.25)	0.28 (0.18–0.41)
HIV-negative TB mortality	0.34 (0.34–0.34)	0.56 (0.55–0.57)
HIV-positive TB mortality	0.031 (0.015–0.054)	0.05 (0.02–0.09)

## Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	2.8% (1.8–4.3)
Previously treated cases	13% (7.7–21)

## TB case notifications, 2018

Total new and relapse	3 777
- % tested with rapid diagnostics at time of diagnosis	0%
- % with known HIV status	
- % pulmonary	71%
- % bacteriologically confirmed <sup>ooo</sup>	80%
- % children aged 0–14 years	4%
- % women	31%
- % men	65%
Total cases notified	3 912

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	88% (77–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	9% (7–10)

## TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive		
- on antiretroviral therapy		

## Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance <sup>ooo</sup>	
- New cases	104%
- Previously treated cases	79%
Laboratory-confirmed cases*	MDR/RR-TB: 62, XDR-TB: 6
Patients started on treatment**	MDR/RR-TB: , XDR-TB:
MDR/RR-TB cases tested for resistance to second-line drugs	47

## Treatment success rate and cohort size

	Success	Cohort
New cases registered in 2017		
Previously treated cases registered in 2017		
HIV-positive TB cases registered in 2017		
MDR/RR-TB cases started on second-line treatment in 2016		
XDR-TB cases started on second-line treatment in 2016		

## TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

## TB financing, 2019

National TB budget (US\$ millions)	
------------------------------------	--

<sup>o</sup> Ranges represent uncertainty intervals

<sup>oo</sup> MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


<sup>ooo</sup> Calculated for pulmonary cases only

\* Includes cases with unknown previous TB treatment history

\*\* Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




— Total TB incidence  
— New and relapse TB cases notified  
— HIV-positive TB incidence

(Rate per 100 000 population per year)



— HIV-negative TB mortality

## Notified cases by age group and sex, 2018



■ Females ■ Males □ Incidence

## Treatment success rate (%)



— New cases  
— Previously treated cases  
— HIV-positive — MDR/RR-TB — XDR-TB